PMID- 19224892 OWN - NLM STAT- MEDLINE DCOM- 20090625 LR - 20140730 IS - 1468-2044 (Electronic) IS - 0003-9888 (Linking) VI - 94 IP - 6 DP - 2009 Jun TI - Lifestyle intervention in obese children with non-alcoholic fatty liver disease: 2-year follow-up study. PG - 437-42 LID - 10.1136/adc.2008.143594 [doi] AB - OBJECTIVE: Non-alcoholic fatty liver disease (NAFLD) is the most common cause of liver disease in obese youth. Lifestyle intervention was demonstrated to improve NAFLD but follow-up studies after end of intervention are lacking. Furthermore the necessary degree of overweight reduction for improvement of NAFLD remains unknown. METHODS: We examined standard deviation score of body mass index (SDS-BMI) and transaminases in 152 obese children with NAFLD diagnosed by ultrasound at baseline, at the end of a 1-year intervention and 2 years after baseline. Within-subject changes of these parameters were compared by participation in the intervention based on physical activity, nutrition education and behaviour therapy. RESULTS: In contrast to 43 children without lifestyle intervention, participation in lifestyle intervention (n = 109) was associated with a significant decrease of transaminases and overweight 1 and 2 years after baseline (1 year: alanine transaminase (ALT) -10 U/l (-14 to -6); aspartate transaminase (AST) -5 U/l (-7 to -3); SDS-BMI -0.23 (-0.30 to -0.16); 2 years: ALT -9 U/l (-12 to -6); AST -6 U/l (-7 to -4); SDS-BMI -0.30 (-0.37 to -0.22); data as mean changes and 95% confidence interval compared to baseline). Any degree of overweight reduction was associated with a significant decrease of NAFLD prevalence. The greatest decrease of NAFLD prevalence (1 year: -89% (95% CI -72% to -100%); 2 years: -94% (95% CI -83% to -100%)) was observed in children with the greatest overweight reduction (SDS-BMI decrease >0.5). CONCLUSIONS: Multidisciplinary lifestyle intervention is effective to improve NAFLD even in the 1-year follow-up after the end of intervention. A minimal reduction of overweight led to an improvement of NAFLD. TRIAL REGISTRATION NUMBER: NCT00435734. FAU - Reinehr, T AU - Reinehr T AD - Vestische Hospital for Children and Adolescents, University of Witten-Herdecke, Datteln, Germany. T.Reinehr@kinderklinik-datteln.de FAU - Schmidt, C AU - Schmidt C FAU - Toschke, A M AU - Toschke AM FAU - Andler, W AU - Andler W LA - eng SI - ClinicalTrials.gov/NCT00435734 PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20090217 PL - England TA - Arch Dis Child JT - Archives of disease in childhood JID - 0372434 RN - 0 (Blood Glucose) RN - EC 2.6.1.1 (Aspartate Aminotransferases) RN - EC 2.6.1.2 (Alanine Transaminase) SB - IM MH - Adolescent MH - Alanine Transaminase/metabolism MH - Anthropometry MH - Aspartate Aminotransferases/metabolism MH - Blood Glucose/metabolism MH - Body Mass Index MH - Child MH - Fatty Liver/etiology/metabolism/*therapy MH - Female MH - Follow-Up Studies MH - Germany MH - Health Behavior MH - Humans MH - Longitudinal Studies MH - Male MH - Obesity/complications/metabolism/*therapy MH - Practice Guidelines as Topic MH - Risk Reduction Behavior MH - Time Factors MH - Weight Loss/physiology EDAT- 2009/02/20 09:00 MHDA- 2009/06/26 09:00 CRDT- 2009/02/20 09:00 PHST- 2009/02/20 09:00 [entrez] PHST- 2009/02/20 09:00 [pubmed] PHST- 2009/06/26 09:00 [medline] AID - adc.2008.143594 [pii] AID - 10.1136/adc.2008.143594 [doi] PST - ppublish SO - Arch Dis Child. 2009 Jun;94(6):437-42. doi: 10.1136/adc.2008.143594. Epub 2009 Feb 17.